SecBot SecBot

Protecting Patient Access to Cancer and Complex Therapies Act

H.R. 4299 Rep. Gregory Murphy (R-NC-3) In committee
Bill text PDF
  1. Introduced Jul 7
  2. Committee Jul 7
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jul 7, 2025Next: House vote
477d ago Jul 7, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
11companies, 63 filings
Subscribe to see spend
Member trades
27trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

11 companies
Companies by sector
Biotech & Pharma 8Medical Devices & Healthcare 3
Search all 11 companies, their asks and price moves Subscribe

Summary

This bill amends the Social Security Act to require manufacturers of certain drugs and biological products that are subject to maximum fair price negotiation under Medicare Part B to pay a rebate to the Secretary of Health and Human Services. The rebate is based on the difference between the current payment amount (ASP+6) and the payment amount using the maximum fair price (MFP+6), and it aims to adjust payments and beneficiary coinsurance accordingly.

Sec. 2, Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation: The bill establishes a new rebate requirement for manufacturers of selected drugs that have a maximum fair price in effect. For each calendar quarter starting after the initial price applicability period, the Secretary must report to each manufacturer the total units of the drug furnished under Part B, the sum of the excess of the ASP+6 payment amount over the MFP+6 payment amount (minus coinsurance), and the excess of the ASP+6 coinsurance amount over the MFP+6 coinsurance amount. The manufacturer must then pay a rebate equal to that sum multiplied by the number of units, within 30 days of receiving the information. The rebate is deposited into the Federal Supplementary Medical Insurance Trust Fund. Beneficiary coinsurance for such drugs is calculated based on the MFP+6 payment amount, unless an inflation rebate applies, in which case the lesser coinsurance amount is used. The bill also makes conforming amendments to ensure that the rebate is reflected in payment amounts, cost-sharing, and calculations for ambulatory surgical centers, outpatient prospective payment systems, and the average sales price, and it coordinates with Medicaid rebate information disclosures.

Summary of the bill text as introduced in House (Jul 7, 2025), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.